Cargando…
Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ
In situ tumor ablation techniques, like radiotherapy, cryo- and heat-based thermal ablation are successfully applied in oncology for local destruction of tumor masses. Although diverse in technology and mechanism of inducing cell death, ablative techniques share one key feature: they generate tumor...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079760/ https://www.ncbi.nlm.nih.gov/pubmed/33936033 http://dx.doi.org/10.3389/fimmu.2021.617365 |
_version_ | 1783685281645330432 |
---|---|
author | van den Bijgaart, Renske J. E. Schuurmans, Fabian Fütterer, Jurgen J. Verheij, Marcel Cornelissen, Lenneke A. M. Adema, Gosse J. |
author_facet | van den Bijgaart, Renske J. E. Schuurmans, Fabian Fütterer, Jurgen J. Verheij, Marcel Cornelissen, Lenneke A. M. Adema, Gosse J. |
author_sort | van den Bijgaart, Renske J. E. |
collection | PubMed |
description | In situ tumor ablation techniques, like radiotherapy, cryo- and heat-based thermal ablation are successfully applied in oncology for local destruction of tumor masses. Although diverse in technology and mechanism of inducing cell death, ablative techniques share one key feature: they generate tumor debris which remains in situ. This tumor debris functions as an unbiased source of tumor antigens available to the immune system and has led to the concept of in situ cancer vaccination. Most studies, however, report generally modest tumor-directed immune responses following local tumor ablation as stand-alone treatment. Tumors have evolved mechanisms to create an immunosuppressive tumor microenvironment (TME), parts of which may admix with the antigen depot. Provision of immune stimuli, as well as approaches that counteract the immunosuppressive TME, have shown to be key to boost ablation-induced anti-tumor immunity. Recent advances in protein engineering have yielded novel multifunctional antibody formats. These multifunctional antibodies can provide a combination of distinct effector functions or allow for delivery of immunomodulators specifically to the relevant locations, thereby mitigating potential toxic side effects. This review provides an update on immune activation strategies that have been tested to act in concert with tumor debris to achieve in situ cancer vaccination. We further provide a rationale for multifunctional antibody formats to be applied together with in situ ablation to boost anti-tumor immunity for local and systemic tumor control. |
format | Online Article Text |
id | pubmed-8079760 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80797602021-04-29 Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ van den Bijgaart, Renske J. E. Schuurmans, Fabian Fütterer, Jurgen J. Verheij, Marcel Cornelissen, Lenneke A. M. Adema, Gosse J. Front Immunol Immunology In situ tumor ablation techniques, like radiotherapy, cryo- and heat-based thermal ablation are successfully applied in oncology for local destruction of tumor masses. Although diverse in technology and mechanism of inducing cell death, ablative techniques share one key feature: they generate tumor debris which remains in situ. This tumor debris functions as an unbiased source of tumor antigens available to the immune system and has led to the concept of in situ cancer vaccination. Most studies, however, report generally modest tumor-directed immune responses following local tumor ablation as stand-alone treatment. Tumors have evolved mechanisms to create an immunosuppressive tumor microenvironment (TME), parts of which may admix with the antigen depot. Provision of immune stimuli, as well as approaches that counteract the immunosuppressive TME, have shown to be key to boost ablation-induced anti-tumor immunity. Recent advances in protein engineering have yielded novel multifunctional antibody formats. These multifunctional antibodies can provide a combination of distinct effector functions or allow for delivery of immunomodulators specifically to the relevant locations, thereby mitigating potential toxic side effects. This review provides an update on immune activation strategies that have been tested to act in concert with tumor debris to achieve in situ cancer vaccination. We further provide a rationale for multifunctional antibody formats to be applied together with in situ ablation to boost anti-tumor immunity for local and systemic tumor control. Frontiers Media S.A. 2021-04-14 /pmc/articles/PMC8079760/ /pubmed/33936033 http://dx.doi.org/10.3389/fimmu.2021.617365 Text en Copyright © 2021 van den Bijgaart, Schuurmans, Fütterer, Verheij, Cornelissen and Adema https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology van den Bijgaart, Renske J. E. Schuurmans, Fabian Fütterer, Jurgen J. Verheij, Marcel Cornelissen, Lenneke A. M. Adema, Gosse J. Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ |
title | Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ
|
title_full | Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ
|
title_fullStr | Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ
|
title_full_unstemmed | Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ
|
title_short | Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ
|
title_sort | immune modulation plus tumor ablation: adjuvants and antibodies to prime and boost anti-tumor immunity in situ |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079760/ https://www.ncbi.nlm.nih.gov/pubmed/33936033 http://dx.doi.org/10.3389/fimmu.2021.617365 |
work_keys_str_mv | AT vandenbijgaartrenskeje immunemodulationplustumorablationadjuvantsandantibodiestoprimeandboostantitumorimmunityinsitu AT schuurmansfabian immunemodulationplustumorablationadjuvantsandantibodiestoprimeandboostantitumorimmunityinsitu AT futtererjurgenj immunemodulationplustumorablationadjuvantsandantibodiestoprimeandboostantitumorimmunityinsitu AT verheijmarcel immunemodulationplustumorablationadjuvantsandantibodiestoprimeandboostantitumorimmunityinsitu AT cornelissenlennekeam immunemodulationplustumorablationadjuvantsandantibodiestoprimeandboostantitumorimmunityinsitu AT ademagossej immunemodulationplustumorablationadjuvantsandantibodiestoprimeandboostantitumorimmunityinsitu |